phase 5
study 2
idelalisib 1
entospletinib 1
pneumonitis 1
limits 1
combination 1
therapy 1
relapsed 2
refractory 2
cll 1
nhl 1
evaluation 1
international 1
prognostic 3
score 2
ips 2
simpler 1
advanced 1
hodgkin 2
lymphoma 6
modern 1
era 1
ii 3
intergroup 2
trial 4
alisertib 1
peripheral 1
tcell 1
transformed 2
mycosis 1
fungoides 1
swog 1
randomized 1
iii 2
comparing 1
abvd 1
plus 1
radiotherapy 1
stanford 1
v 1
regimen 1
patients 3
stages 1
locally 1
extensive 1
bulky 1
mediastinal 1
subset 1
analysis 2
north 1
american 1
e 1
comparative 1
factor 1
models 1
follicular 1
based 1
choprituximab 1
versus 1
chop 1
iodinetositumomab 1
outcomes 1
burkitt 1
older 1
age 1
treated 1
intensive 1
chemotherapeutic 1
regimens 1
bendamustine 1
rituximabrefractory 1
indolent 1
nonhodgkins 1
results 1
multicenter 1
singleagent 1
